论文部分内容阅读
目的观察诺雪健对急性心肌梗死(AM I)静脉溶栓治疗后再灌注心律失常的影响。方法将288例符合溶栓标准的AM I病人随机分为2组,对照组给予常规治疗,治疗组加用诺雪健300mg静脉滴注,1次/d。观察2组再灌注心律失常发生率的差异。结果治疗组144例,再通131例,再灌注心律失常的发生率56.1%(74/131)。对照组144例,再通120例,再灌注心律失常的发生率73.1%(87/120)。治疗组再灌注心律失常的发生率明显低于对照组(χ2=6.981,P<0.01)。结论诺雪健对AM I溶栓后再灌注心律失常有明显的抑制作用。
Objective To observe the effect of Nuosujian on reperfusion arrhythmia after intravenous thrombolytic therapy of acute myocardial infarction (AMI). Methods A total of 288 AMI patients who were eligible for thrombolysis were randomly divided into two groups. Patients in the control group were given routine treatment. The patients in the treatment group were treated with Norbutron 300mg intravenously once a day. The difference of reperfusion arrhythmia incidence between the two groups was observed. Results The treatment group, 144 cases, 131 cases again, the incidence of reperfusion arrhythmia 56.1% (74/131). Control group, 144 cases, again pass 120 cases, the incidence of reperfusion arrhythmia 73.1% (87/120). The incidence of reperfusion arrhythmia in the treatment group was significantly lower than that in the control group (χ2 = 6.981, P <0.01). Conclusion Nuo-xue-jian has a significant inhibitory effect on reperfusion arrhythmia after AM I thrombolysis.